Format

Send to

Choose Destination
J Neurooncol. 2016 Jun;128(2):293-302. doi: 10.1007/s11060-016-2109-x. Epub 2016 Mar 19.

Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.

Author information

1
Children's Cancer Centre, Royal Children's Hospital, 50 Flemington Road, Parkville, Melbourne, VIC, 3052, Australia. ajdodgshun@gmail.com.
2
Department of Paediatrics, University of Melbourne, Melbourne, VIC, 3052, Australia. ajdodgshun@gmail.com.
3
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, 450 Longwood Ave, Boston, 02115, USA.
4
Harvard Medical School, Boston, MA, USA.
5
Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, 02115, USA.
6
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
7
Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
8
Department of Pathology, Royal Children's Hospital, Melbourne, VIC, 3052, Australia.
9
Department of Neurosurgery, Boston Children's Hospital, Boston, MA, USA.
10
Department of Neurosurgery, Harvard Medical School, Boston, MA, USA.
11
Children's Cancer Centre, Royal Children's Hospital, 50 Flemington Road, Parkville, Melbourne, VIC, 3052, Australia.
12
Murdoch Children's Research Institute, Melbourne, VIC, 3052, Australia.
13
Broad Institute of MIT and Harvard, Cambridge, USA.
14
Department of Pathology, Harvard Medical School, Boston, MA, USA.
15
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
16
Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
17
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, 450 Longwood Ave, Boston, 02115, USA. Pratiti_Bandopadhayay@dfci.harvard.edu.
18
Harvard Medical School, Boston, MA, USA. Pratiti_Bandopadhayay@dfci.harvard.edu.
19
Broad Institute of MIT and Harvard, Cambridge, USA. Pratiti_Bandopadhayay@dfci.harvard.edu.
20
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. Pratiti_Bandopadhayay@dfci.harvard.edu.

Abstract

Disseminated glioneuronal tumors of childhood are rare. We present a retrospective IRB-approved review of the clinical course and frequency of BRAF mutations in disseminated glioneuronal tumors at two institutions. Defining features of our cohort include diffuse leptomeningeal-spread, often with a discrete spinal cord nodule and oligodendroglioma-like histologic features. Patients were identified through a pathology database search of all cases with disseminated low-grade neoplasms with an oligodendroglioma-like component. De-identified clinical information was collected by chart review and all imaging was reviewed. We retrieved the results of targeted genomic analyses for alterations in BRAF. Ten patients (aged 2-14 years) were identified from the Dana-Farber/Boston Children's Hospital and the Royal Children's Hospital, Melbourne pathology databases. Nine patients received chemotherapy. Eight patients are alive, although three have had episodes of progressive disease. We identified genomic alterations affecting the MAPK pathway in six patients. One patient had a germline RAF1 mutation and a clinical diagnosis of cardio-facio-cutaneous syndrome. BRAF duplications were identified in four and BRAF V600E mutation was identified in one. These data support the presence of targetable genomic alterations in this disease.

KEYWORDS:

Glioneuronal; Leptomeningeal neoplasms; Oligodendroglioma; Pediatric glioma; Proto-oncogene proteins B-raf

PMID:
26994902
DOI:
10.1007/s11060-016-2109-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center